Study Finds Finerenone May Benefit CKD Patients Without Diabetes
Study Highlights
An international study has revealed that finerenone, a drug previously studied primarily in diabetic populations, demonstrates significant benefits for individuals with chronic kidney disease who do not have diabetes. The research found that finerenone slows the progression of kidney function decline and reduces the risk of serious kidney and cardiovascular complications.
Clinical Implications
Chronic kidney disease affects millions worldwide, yet treatment options have been particularly limited for the majority of patients who do not have diabetes. This study opens the door to a much-needed new therapeutic approach that could help preserve kidney function and improve cardiovascular outcomes in this underserved patient population.